Merck KGaA has reported strong first-quarter results, prompting an upgrade to its 2026 financial outlook, largely driven by growth in its Life Science and Electronics sectors.
The company recorded net sales of €5.1 billion for Q1, reflecting a 2.8% decline due to currency fluctuations, yet showing a 2.9% organic growth. EBITDA pre remained stable at €1.5 billion, with a notable 5.3% organic growth attributed to heightened demand for semiconductor materials and pharmaceutical manufacturing solutions. As a result, Merck has revised its 2026 projections, anticipating net sales of up to €21.4 billion and EBITDA pre reaching €6.1 billion.
The Life Science division was particularly strong, with Process Solutions achieving a remarkable 16.2% organic growth, surpassing €1 billion in sales. This growth stemmed from increased demand for downstream processing and single-use technologies. Meanwhile, the Healthcare sector faced challenges, with a 3% decline in sales to €2.1 billion, although rare disease therapies continued to drive growth.
Additionally, the Electronics division benefited from the ongoing AI and semiconductor boom, with organic sales in Semiconductor Solutions rising by 7.5%. Despite these positive results, currency fluctuations negatively impacted overall earnings. Merck plans to enhance its focus on integrated customer solutions and expand its AI-driven capabilities to sustain long-term growth.
This strategic pivot indicates Merck's commitment to adapting to evolving market conditions and leveraging its scientific expertise in both the digital and physical realms, positioning itself for future success in the life sciences and technology sectors.